



Sri Devaraj Urs Academy of Higher Education & Research

Comprising Sri Devaraj Urs Medical College

A DEEMED TO BE UNIVERSITY

Research and Development Cell

Declared under Section 3 of UGC Act, 1956, MHRD GOI No.F.9-36/2006-U.3 (A) Dt. 25th May 2007

POST BOX NO.62, TAMAKA, KOLAR-563 101, KARNATAKA, INDIA

Ph.: 08152-243003, 210604, 210605, Fax: 08152-243008, E-mail: co.rd@sduaher.ac.in, website: www.sduaher.ac.in

3.2.1: Grants for research projects/clinical trials sponsored by non-government sources such as industry, corporate houses, international bodies, endowments, professional associations, endowment-Chairs etc in the institution during the year (INR in Lakhs)

Sl. No	Principal Investigator	Details of the project	Sponsoring/Funding Agency	Amount Sanctioned	Amount released	Year	Status
1.	Dr. Kowshick R 2 nd year PG Dr. Pradeep Kumar Associate Professor Department of Community medicine	Are our rural adolescent boys safe from porn addiction? A mixed method study	MAMTA Health Institute for Mother and Child, New Delhi	Rs. 1 Lakh	10,000	2025	In process


Prof. Dr. Kalyani . R.
MD (Path), Ph.D. FAMS, FICP, FEAMS, FIMSA, FRSM
Director
Research and Development Cell, SDUAHER
Professor & Former Head
Dept. of Pathology, SDUMC

SE-151 85
Södertälje,
Schweden, in
adult patients with
carcinoma of the
ovary, breast,
prostate or

adenocarcinoma
of the pancreas
under fasting
condition



Prof. Dr. Kalyani . R.

MD(Path), Ph.D. FAMS, FICP, FIAMS, FIMSA, FKSTA

Director

Research and Development Cell, SDUAHER

Professor & Former Head

Dept. of Pathology, SDUMC

4.

Dr. D. Lokanatha
Professor
Department of
Medical Oncology

Release
Levetiracetam as
Add-on Therapy
in Patients with
Refractory Partial
Onset Epilepsy

A randomized,
open label, multi-
center, two-
treatment, two-
period, two-
sequence, fully
replicate, cross-
over, multiple
dose, steady-state,
bioequivalence
study of Olaparib
Tablets 150 mg
(2*150 mg
tablets) of
Alembic
Pharmaceuticals
Limited, India
with Lynparza®
150mg
Filmtabletten
Olaparib (2*150
mg tablets) of
AstraZeneca AB,


Alembic Pharmaceutical Limited

Rs. 1.99 Lakh Per
Patient

-


2024

In process



Prof. Dr. Kalyani . R.
MD(Path), Ph.D, FAMS, FICP, FIAMS, FIMSA, FRSA
Director
Research and Development Cell, SDUMC
Professor & Former Head
Dept. of Pathology, SDUMC

2.	<p>Dr. D. Lokanatha Professor Department of Medical Oncology</p>	<p>A Prospective, Randomized, Double Blind, Multicentric, Parallel Group Phase-III Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of BP01 (Bevacizumab) Versus EU approved Avastin® along with chemotherapy XELOX in metastatic colorectal cancer patients.</p>	<p>CuraTeQ Biologics Private Limited</p>	<p>Rs.2.37 Lakh per patient</p>	<p>Rs.1.56 Lakh</p>	<p>2024</p>	<p>In process</p>
3.	<p>Dr. Bhuma Vengamma Vice Chancellor, SDUAHER Department of Neurology</p>	<p>A Double-Blind, Randomized, Placebo and Active Controlled Study to Evaluate the Efficacy and Safety of Once Daily, Extended</p>	<p>Neuraxpharm Pharmaceuticals S.L.</p>	<p>Rs.4.26 Lakh Per Patient</p>	<p>-</p>	<p>2024</p>	<p>In process</p>


Prof. Dr. Kalyani . R.
 (M.Phil), Ph.D, FAMS, FICP, FIAMS, FIMSA, FRCR
Director
 Research and Development Cell, SDUAHER
 Professor & Former Head
 Dept. of Pathology, SDUMC